Almirall stock
Price history
−18.05% over the period1 year: from €12.52 (November 20, 2025) to €10.26 (November 20, 2026), −18.05%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| November 20, 2026 | €10.26 |
| October 30, 2026 | €10.60 |
| September 30, 2026 | €10.56 |
| August 31, 2026 | €10.32 |
| July 31, 2026 | €11.10 |
| June 30, 2026 | €11.26 |
| May 29, 2026 | €11.38 |
| April 30, 2026 | €12.58 |
| March 31, 2026 | €12.16 |
| February 27, 2026 | €12.88 |
| January 30, 2026 | €12.62 |
| December 31, 2025 | €12.84 |
| November 28, 2025 | €12.64 |
| November 20, 2025 | €12.52 |
At a glance
The company
Biopharmaceutical company focused on developing and commercializing treatments for skin diseases and other therapeutic areas
Latest results
Quarter to June 30, 2026 · EPS €0.12 (estimate €0.09)
TickerLandia's take on Almirall
- Pricier than usual relative to earnings: P/E on the latest fiscal year 48 vs a median of 33 over its last 6 fiscal years.
- Pricier than similar companies: trailing 12-month P/E 30 vs 19 (+56%) in a group of 10.
- Strong point: Growth (64/100 in its group). Weak point: Profitability (28/100).
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
−26.61% from the 52-week high
Analysts · 11 analysts
Average target€14.28+39.21% vs. price
Buy 10 · Hold 1 · Sell 0 · Strong buy
TickerLandia Fingerprint: Almirall
Compared with similar companies: low profitability, weak momentum, and low price.
Financials and price compared with 39 companies in the drug manufacturers - specialty & generic industry, worldwide. Momentum and risk compared with 1,160 European stocks.
Pricelow32
How much it costs relative to what it produces.
Metric Value Position in group P/E (trailing 12 months) 30.2 59 Forward P/E 20.0 51 EV/EBITDA 8.61 18 Price/sales 1.89 22 Price/book 1.45 12 Profitabilitylow28
How much it earns on revenue and capital.
Metric Value Position in group ROE 4.0% 14 ROA 3.0% 17 Operating margin 9.6% 17 Gross margin 75.9% 73 Net margin 5.1% 19 Earnings stabilitylow35
How steady its margins were over the last five annual reports.
Metric Value Position in group Margin variabilitycounts in reverse: lower means more earnings stability 3.3% 51 Loss-making yearscounts in reverse: lower means more earnings stability 2 of 5 annual reports 18 Growthhigh64
How fast revenue and earnings are growing.
Metric Value Position in group Average revenue growth (3 years) +8.26% 54 Revenue growth (year over year) +9.80% 39 Earnings growth (year over year) +435.11% 99 Financial strengthaverage52
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Debt/equitycounts in reverse: lower means more financial strength 0.18 72 Current ratio 2.51 63 Net debt/EBITDAcounts in reverse: lower means more financial strength 0.04 61 Interest coverage 4.24 14 Dividendaverage60
How much it returns to shareholders, and for how long.
Metric Value Position in group Dividend yield 1.9% 56 Consecutive dividend years 12 years 44 Payout ratio 55.0% 79 Market momentumweak32
How the stock has moved compared with the market.
Metric Value Position in group Relative strength (3 months) +3.56% 58 Relative strength (6 months) −13.77% 28 1-year return −18.05% 13 Distance from 200-day average −9.19% 27 Riskaverage44
How much the price swings.
Metric Value Position in group Beta (1 year) 0.45 23 Volatility (60 days) 26.0% 43 Maximum drawdown (12 months) 28.9% 65
Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 22, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
Almirall is pricier than in the past and pricier than similar companies
On the latest fiscal year's earnings (2025), Almirall's P/E today is 47.6, above the median of its last 6 fiscal years (33.2; between 25.2 and 173.7 from 2016 to 2025). Almirall's P/E (trailing 12 months): 30.2, +56% against the median of a group of 10 similar companies (19.4).
Compared with 10 similar companies
| Metric | Almirall | Position in the group | Band |
|---|---|---|---|
| P/E (trailing 12 months) | 30.2 | High | |
| Forward P/E | 20.0 | Middle | |
| Operating margin | 9.6% | Low | |
| ROE | 4.0% | Low | |
| Debt/equity | 0.18 | Low |
P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: Almirall. All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Revenue
€313.23M
Latest quarter · Q2 2026
Net income
€24.25M
Latest quarter · Q2 2026
Quarterly net margin
7.7%
Latest quarter · Q2 2026
Numbers and valuation
Full valuation- Market cap
- €2.23B
- P/E
- 30.2
- EPS
- €0.34
- Volume
- 114.85K
- Daily trading
- €1.64M
- Dividend yield
- 1.82%
- Last ex-dividend on May 14, 2026
How Almirall is changing
All resultsRevenue grew 6.5% a year on average over the last 5 years
Operating margin fell from 7.7% to 6.4%
Shares outstanding up 19.6% in 5 years
Returns
Almirall returns with dividends
€1,000 invested in Almirall 5 years ago, on November 22, 2021, would be worth €1,091 today with dividends reinvested: +9.08% in total, +1.76% per year. On price alone it would be €994 (−0.58%).
| Period | Almirall | IBEX 35 | €1,000 becomes |
|---|---|---|---|
| 1 month | −0.77% | −1.15% | €992 |
| 6 months | −9.84% | +4.55% | €902 |
| Year to date | −20.09% | +9.04% | €799 |
| 1 year | −16.72% | +18.04% | €833 |
| 3 years | +27.36% | +91.82% | €1,274 |
| 5 years | +9.08% | +113.95% | €1,091 |
| 10 years | −16.54% | +119.08% | €835 |
Over the last 6 months it has done better than 10% of the stocks in the Healthcare sector.
From 1 year up with dividends reinvested, before taxes; under a year price only. IBEX 35: price only. Calculate your investment
The chart in detail
Almirall: technical analysis
Almirall is in a downtrend: the price is below its 50- and 200-session moving averages, and the 200-session average is falling. The price is 46.6% below its all-time closing high (€19.22, August 18, 2015).
- Trend
- Downward
- RSI (14 sessions)
- 42
- Between 30 and 70
- vs 200-session average
- −9.19%
Support and resistance
Price areas where Almirall has stopped several times in the last year. They describe the chart; they are not forecasts.
- Resistance€11.07+7.93%3 touches, last on July 1, 2026
- Resistance€10.85+5.72%3 touches, last on September 16, 2026
- Resistance€10.52+2.53%7 touches, last on November 9, 2026
- Last price€10.26
- Support€10.23−0.32%3 touches, last on September 1, 2026
- Support€10.03−2.24%2 touches, last on October 28, 2026
Volatility and risk
Over the last year it has moved less than the IBEX 35.
- Beta (1 year) vs IBEX 35
- 0.45
- Volatility (60 sessions, annualised)
- 26.0%
- Largest fall in the last year
- −28.87%
Close of November 20, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
Almirall: seasonality
Average monthly price change over 20 years
Over the last 20 years, the strongest month for Almirall has been January: +5.12% on average, positive in 14 years out of 19. The weakest has been September: −2.19% on average, positive in 12 years out of 20. November, the current month, has been positive in 9 years out of 19 (−0.58% on average).
Show chart data
| Month | Average | Median | Positive years |
|---|---|---|---|
| January | +5.12% | +3.30% | 14 of 19 |
| February | +0.74% | +2.06% | 12 of 19 |
| March | +0.09% | −2.44% | 7 of 19 |
| April | +1.94% | +2.97% | 11 of 19 |
| May | +0.67% | +0.42% | 10 of 19 |
| June | −2.15% | −1.78% | 6 of 19 |
| July | −1.51% | +0.17% | 10 of 20 |
| August | +1.22% | −1.26% | 9 of 20 |
| September | −2.19% | +0.69% | 12 of 20 |
| October | +1.67% | +1.68% | 12 of 20 |
| November | −0.58% | −0.86% | 9 of 19 |
| December | −0.70% | +0.33% | 10 of 19 |
Price change only, dividends excluded. Past seasonality does not predict future moves.
The company
Almirall and its competitors
Operating from Barcelona since 1943, Almirall develops and sells products focused on skin health, with its main therapeutic emphasis on skin diseases such as psoriasis, atopic dermatitis, acne and actinic keratosis. Its portfolio also covers cardiovascular, respiratory and nervous system medicines. Sales reach Spain, the rest of Europe, the Middle East, the United States, Asia and Africa. The pipeline includes candidates for psoriatic arthritis and pediatric atopic dermatitis, along with earlier-stage programs in hidradenitis suppurativa and alopecia areata.
- Headquarters
- Barcelona, Spain
- Employees
- 2,108
- Founded
- 1943
- Chief executive
- Carlos Gallardo Piqué
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| AlmirallALM | $2.45B | 9.6% | 30.2 | −9.84% |
| FagronFAGR | $1.97B | 14.3% | 19.5 | −0.20% |
| Siegfried HoldingSFZN | $3.4B | 16.7% | 16.7 | −19.46% |
| Faes FarmaFAE | $1.65B | 13.0% | 17.9 | +4.66% |
| Laboratorios Farmaceuticos RoviROVI | $3.68B | 20.2% | 16.0 | +5.25% |
| PharmaNutraPHN | $917.61M | 22.0% | 36.7 | −2.50% |
Same industry or related industries, similar size. Compare Almirall with its competitors · Full profile
